Pfizer and the Medicines Patent Pool sign a global licensing agreement that will allow Pfizer's experimental COVID-19 oral drugPaxlovid to be manufactured under a royalty-free license in 95 low and middle-income countries.
Pfizer and Medicines Patent Pool sign a global licensing agreement that will allow its experimental COVID-19 oral drug Paxlovoid to manufactured and grant royalty-free license in 95 low and middle-income countries.
Pfizer and theMedicines Patent Pool sign a global licensing agreement that will allow Pfizer's experimental COVID-19 oral drug Paxlovid to bemanufactured undera royalty-free license in 95 low and middle-income countries.
